



# Erdheim-Chester Disease Medical Symposium **Agenda**

November 16, 2021 | 9:00 am to 2:15 pm CT

MINUTES	SESSION / SPEAKER
9:00	<i>Housekeeping and Technical Instructions</i>
9:05	<b>WELCOME FROM THE ECD GLOBAL ALLIANCE</b> <b>Kathy Brewer</b> <i>President</i>
9:25	<b>ECD PATIENT REGISTRY OVERVIEW &amp; UPDATE</b> <b>Eli L. Diamond, MD</b> <i>Memorial Sloan Kettering</i>

## BASIC SCIENCE

9:45	Oncogene-Induced Maladaptive Activation of Trained Immunity in the Pathogenesis and Treatment of Erdheim-Chester Disease <b>Giulio Cavalli, MD, PhD</b>   <i>IRCCS San Raffaele Scientific Institute, Milan, Italy</i>
10:05	Disturbance of monocyte homeostasis in histiocytosis is close to chronic myelomonocytic leukemia and is correlated with phenotype and disease activity <b>Razanamahery Jerome, MD</b>   <i>Pitié-Salpêtrière Hospital, Paris, France</i>
10:25	Novel recurrent mutations in Erdheim-Chester Disease patients identified by whole-exome sequencing and whole-genome sequencing <b>Yu Oyama, MD</b>   <i>The University of Tokyo, Tokyo, Japan</i>
10:45	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim–Chester Disease <b>Oshrat Rokah, Ph.D.</b>   <i>Assuta Medical Center, Tel-Aviv, Israel</i>

## CASE STUDIES

11:05	Dramatic efficacy of Vemurafenib on psychiatric symptoms revealing <i>BRAFV600E</i> Erdheim-Chester Disease <b>Razanamahery Jerome, MD</b>   <i>Dijon University Hospital, Dijon, France</i>
11:25	Synchronic Systemic Aggressive Mastocytosis and Langerhans Cell Histiocytosis with <i>BRAF p.N486_P490del</i> <b>André Neder Ramires Abdo, MD</b>   <i>Oncology Center at Hospital Alemão Oswaldo Cruz, São Paulo</i>

## BREAK – 15 MINUTES



# Erdheim-Chester Disease Medical Symposium **Agenda**

November 16, 2021 | 9:00 am to 2:15 pm CT

**MINUTES** | **SESSION / SPEAKER**

## ORGAN INVOLVEMENT

11:45	Role of vascular endothelial growth factor in Erdheim-Chester Disease <b>Anaïs Roeser, MD</b>   <i>Assistance Publique Hôpitaux de Paris, Paris, France</i>
12:05	Kidney involvement in Erdheim-Chester disease: a multicenter cohort study on 195 patients <b>Francesco Pegoraro, MD</b>   <i>Meyer University Children's Hospital, Firenze, Italy</i>

## TREATMENTS

12:25	Treatment of Non-Langerhans Cell Histiocytosis with the MEK Inhibitor Trametinib <b>Ashley Aaroe, MD</b>   <i>MD Anderson Cancer Center, Houston, TX, USA</i>
12:45	Outcomes after discontinuing targeted therapy in ECD and other histiocytoses <b>Eli L. Diamond, MD</b>   <i>Memorial Sloan Kettering, New York, NY, USA</i>

## Q&A WITH EXPERT PANEL

1:05	Leading physicians in various specialties answer attendee questions.
------	--

## INTERNATIONAL UPDATES

(5-MINUTE PRE-RECORDINGS MAY BE PLAYED IN BETWEEN OTHER SESSIONS OR AT THE END OF MEETING)

1:35	<ul style="list-style-type: none"><li>· <i>The Netherlands - Dr. Jam van Laar</i></li><li>· <i>Brazil - Dr. Andre Abdo</i></li><li>· <i>Australia - Dr. Michael Dickinson</i></li><li>· <i>Israel - Dr. Roei Mazor</i></li></ul>	<ul style="list-style-type: none"><li>· <i>UK - Dr. Tal Munir</i></li><li>· <i>The UK - Dr. Matthew Collin</i></li><li>· <i>Italy - Dr. Augusto Vaglio</i></li><li>· <i>China – Dr. Xinxin Cao</i></li></ul>
------	--	--

## CLOSING

2:10	+ Invitation to join the next meeting in April 2022 + Request evaluation + More information
------	---